0955 GMT - A U.S. investigation into pharmaceutical imports and potential tariffs in the coming months will likely limit clarity from pharma companies during their 1Q results, Barclays analysts say in a note. The investigation, initiated April 1, aims to assess the national security implications of pharmaceutical imports, including finished generics, nongenerics and active pharmaceutical ingredients, and has to be finalized in around nine months. "With Pharma having been excluded from the initial reciprocal tariffs and it being our house view that some sort of Commerce Department investigation being required for these sectoral tariffs, this isn't too surprising but at least provides some timing framing," they say. Barclays analysts estimate that AstraZeneca, Roche and Grifols appear most insulated, whereas GSK and Sandoz look most exposed to a potential tariff risk. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
April 15, 2025 05:55 ET (09:55 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。